Clinical trials: Patient With Colorectal Cancer
Advanced Colorectal Cancer
Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
This trial will evaluate the efficacy of PM060184 in terms of progression-free survival at 12 weeks (PFS3) in advanced or metastatic Colorectal Cancer (CRC) patients with any KRAS mutation status (wild- type; mutated; or unknown…
- Trial name
- NCT03427268
- Testing
- PM060184
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 32 people
- Sponsor
- PharmaMar
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Oligometastases
SABR-SCAN Trial for Pulmonary Oligometastases
Rationale: SABR (Stereotactic ablative radiotherapy) is one of the standard treatment options besides surgical resection for limited lung metastases (oligometastases) from colorectal cancer.
- Trial name
- SABR-SCAN (NCT02414334)
- Testing
- Stereotactic Ablative Radiotherapy (SABR)
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- University Medical Center Groningen
Colorectal Cancer
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation therapy) prior to surgery.
- Trial name
- NCT01515787
- Testing
- FOLFOX (chemotherapy), 5 FUCMT (chemoradiation), surgery
- Where
- 1,073 sites in United States, Canada and 2 more
- Volunteers
- 1,194 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer
Evaluation of Short-term Outcomes of Day Surgery for Patients With CuRC
To evaluate the feasibility and safety of laparoscopic colectomy and anterior resection for patients with colon/upper rectal cancer (CuRC) in day surgery center.
- Trial name
- NCT04646915
- Testing
- Day surgery
- Where
- China
- Volunteers
- 120 people
- Sponsor
- West China Hospital
Colorectal Cancer
A Mobile Aplication for the Promotion of Healthy Lifestyle Habits in Patients With Colorectal Cancer
The purpose of this randomized study is to assess the efficacy of a mobile application for the promotion of healthy lifestyle habits (diet and exercise) in colorectal cancer survivors (CCR).
- Trial name
- NCT02837159
- Testing
- mHealth application
- Where
- Spain
- Sponsor
- Universidad de Granada
Metastatic Colorectal Cancer
Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer
Phase I Study of biweekly combination therapy with S-1, Irinotecan, and Bevacizumab as 1-line Chemotherapy in Patients With Advanced Colorectal Cancer.
- Trial name
- SIRB2 (NCT03380689)
- Testing
- S-1, Irinotecan, Bevacizumab
- Where
- China
- Sponsor
- Fujian Cancer Hospital
Colorectal Cancer, Head and Neck Cancer
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Cetuximab in patients with Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell…
- Trial name
- NCT02110082
- Testing
- Urelumab, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Bristol-Myers Squibb
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Metastatic Colorectal Cancer
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
This study will investigate whether the combination of PF-05212384 plus Irinotecan improves progression free survival in patients with KRAS and NRAS wild type metastatic colorectal cancer when compared with the combination of…
- Trial name
- NCT01925274
- Testing
- PF-05212384, irinotecan, Cetuximab
- Where
- 32 sites in United States, Japan and 2 more
- Volunteers
- 19 people
- Sponsor
- Pfizer
Colonic Cancer, Metastasis
Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer
Oral curcumin (complex C3, Sabinsa Corp, Utah) will be given to patients with inoperable colorectal metastases who will be commencing standard care oxaliplatin-based (FOLFOX) chemotherapy for up to 12 cycles(approximately 6…
- Trial name
- CUFOX (NCT01490996)
- Testing
- Oral complex C3 curcumin + chemotherapy, Chemotherapy only
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- University of Leicester
Colorectal Cancer, Colon Cancer
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
This study has two portions. The main goal of the Phase I portion of this research study is to see what doses of CB-839 and capecitabine can safely be given to patients without having too many side effects.
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer, Solid Tumor
- Trial name
- NCT02861300
- Testing
- CB-839, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- David Bajor, MD
Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
This phase II trial studies the side effects of erlotinib hydrochloride and how well it works in reducing duodenal polyp burden in patients with familial adenomatous polyposis at risk of developing colon cancer.
- Trial name
- NCT02961374
- Testing
- Erlotinib, Erlotinib Hydrochloride
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer
The purpose of the study is to evaluate the safety and efficacy of FOLFIRI (Irinotecan, Leucovorin and 5 Fluorouracil) chemotherapy when combined with sunitinib or FOLFIRI chemotherapy without adding sunitinib as the first line…
- Trial name
- NCT00457691
- Testing
- 5 fluorouracil, irinotecan, levo- leucovorin
- Where
- 132 sites in Argentina, Australia and 32 more
- Volunteers
- 768 people
- Sponsor
- Pfizer
Rectal Cancer
Open or Laparoscopic Mesolectal Excision in Low Rectum Cancer
To compare the open approach and the laparoscopic-assisted approach of dissection of lateral lymph nodes in low advanced rectal cancer patients with clinically suspected nodal metastases in terms of safety, technical feasibility…
- Trial name
- NCT04561830
- Testing
- laparoscopic-assited excision of mesorectum with pelvic lymph nodes excision
- Volunteers
- 60 people
- Sponsor
- Zagazig University
Metastatic Colorectal Cancer
Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study
This study aimis at detecting the genomic changes of ctDNA in patients of RAS and BRAF wild-type mCRC, who failed after first line treatment containing cetuximab.
- Trial name
- NCT04831528
- Testing
- Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others
- Volunteers
- 100 people
- Sponsor
- Fudan University
Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer
QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer
This is a multicenter, prospective, phase II study evaluating total neoadjuvant therapy (TNT) consisting of short-course radiotherapy (SCRT; 5×5 Gy) followed by QL1706 (a bifunctional MabPair antibody targeting PD-1 and CTLA-4…
- Conditions
- Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer, Non-metastatic Rectal Cancer
- Trial name
- NCT07175636
- Testing
- Drug: QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy (SCRT)
- Volunteers
- 66 people
- Sponsor
- Sun Yat-sen University
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer
Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient
This is a phase II randomized study of 4-months induction first-line chemotherapy with FOLFOXIRI + cetuximab followed by maintenance with cetuximab or bevacizumab in patients affected by KRAS wild type (wt) mCRC.
- Trial name
- MACBETH (NCT02295930)
- Testing
- folfoxiri+cetuximab+surgery+cetuximab, folfoxiri+cetuximab+surgery+bevacizumab
- Where
- 22 sites in Italy
- Volunteers
- 143 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Rectal Cancer
Preoperative Chemoradiation With Capecitabine and Cetuximab
feasibility and tolerance of preoperative therapy with Cetuximab in combination with Capecitabine and radiotherapy for patients with locally advanced operable rectal carcinoma collection of response rate (T-downstaging…
- Trial name
- NCT00297128
- Testing
- Capecitabine, Cetuximab
- Where
- 10 sites in Austria
- Volunteers
- 31 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.